Prevalence of HPV after introduction of the vaccination program in the United States

LE Markowitz, G Liu, S Hariri, M Steinau, EF Dunne… - …, 2016 - publications.aap.org
BACKGROUND: Since mid-2006, human papillomavirus (HPV) vaccination has been
recommended for females aged 11 to 12 years and through 26 years if not previously …

Trends in human papillomavirus vaccine safety concerns and adverse event reporting in the United States

K Sonawane, YY Lin, H Damgacioglu, Y Zhu… - JAMA Network …, 2021 - jamanetwork.com
Importance In the US, safety concern has been identified as a primary barrier to initiating the
human papillomavirus (HPV) vaccine. It is unclear if the public's sentiment concerning HPV …

Human papillomavirus molecular biology

ME Harden, K Munger - Mutation Research/Reviews in Mutation Research, 2017 - Elsevier
Human papillomaviruses are small DNA viruses with a tropism for squamous epithelia. A
unique aspect of human papillomavirus molecular biology involves dependence on the …

[HTML][HTML] Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from …

M Brisson, É Bénard, M Drolet, JA Bogaards… - The Lancet Public …, 2016 - thelancet.com
Background Modelling studies have been widely used to inform human papillomavirus
(HPV) vaccination policy decisions; however, many models exist and it is not known whether …

An update on human papilloma virus vaccines: history, types, protection, and efficacy

Z Yousefi, H Aria, F Ghaedrahmati, T Bakhtiari… - Frontiers in …, 2022 - frontiersin.org
Human papillomavirus (HPV) is the most common sexually transmitted agent worldwide.
Early prevention with HPV vaccination is a safe and effective method against this disease …

Triage of HPV positive women in cervical cancer screening

N Wentzensen, M Schiffman, T Palmer… - Journal of Clinical …, 2016 - Elsevier
Despite HPV vaccines, screening will remain central for decades to control cervical cancer.
Recently, HPV testing alone or with cytology was introduced as an alternative to cytology …

[HTML][HTML] Therapeutic vaccines for high-risk HPV-associated diseases

A Chabeda, RJR Yanez, R Lamprecht, AE Meyers… - Papillomavirus …, 2018 - Elsevier
Cancer is the second leading cause of death worldwide, and it is estimated that Human
papillomavirus (HPV) related cancers account for 5% of all human cancers. Current HPV …

High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis

NSL Yeo-Teh, Y Ito, S Jha - International journal of molecular sciences, 2018 - mdpi.com
Infection with high-risk human papillomavirus (HPV) has been linked to several human
cancers, the most prominent of which is cervical cancer. The integration of the viral genome …

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

AR Kreimer, F Struyf… - The lancet …, 2015 - thelancet.com
Background There is some evidence to suggest that one or two doses of the HPV vaccine
provides similar protection to the three-dose regimen. The main aim of the study was to …

The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease

AR Garbuglia, D Lapa, C Sias… - Frontiers in …, 2020 - frontiersin.org
Human papillomavirus (HPV) is the most common sexually transmitted virus. The high-risk
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …